Who are Angal S, topical spray [Menthol]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo with 0.09% menthol gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/angal-s-topical-spray-menthol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Angal S, topical spray [Menthol] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Angal S, topical spray [Menthol] (Angal S, topical spray [Menthol]) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical analgesic/counterirritant. Area: Pain Management.

phase 3 Topical analgesic/counterirritant TRPM8 (transient receptor potential melastatin 8) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Angal S, topical spray [Menthol] (Angal S, topical spray [Menthol]) — Sandoz. Menthol produces a cooling sensation by activating TRPM8 cold-sensitive receptors on nerve endings, providing topical analgesic and anti-inflammatory relief.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Angal S, topical spray [Menthol] TARGET	Angal S, topical spray [Menthol]	Sandoz	phase 3	Topical analgesic/counterirritant	TRPM8 (transient receptor potential melastatin 8)
Placebo with 0.09% menthol gel	Placebo with 0.09% menthol gel	GlaxoSmithKline	phase 3	Topical analgesic/counterirritant	TRPM8 (transient receptor potential melastatin 8)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical analgesic/counterirritant class)

GlaxoSmithKline · 1 drug in this class
Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Angal S, topical spray [Menthol] — Competitive Intelligence Brief. https://druglandscape.com/ci/angal-s-topical-spray-menthol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab